AU2003302072A1 - Palonosetron for the treatment of chemotherapy-induced emesis - Google Patents

Palonosetron for the treatment of chemotherapy-induced emesis

Info

Publication number
AU2003302072A1
AU2003302072A1 AU2003302072A AU2003302072A AU2003302072A1 AU 2003302072 A1 AU2003302072 A1 AU 2003302072A1 AU 2003302072 A AU2003302072 A AU 2003302072A AU 2003302072 A AU2003302072 A AU 2003302072A AU 2003302072 A1 AU2003302072 A1 AU 2003302072A1
Authority
AU
Australia
Prior art keywords
palonosetron
chemotherapy
treatment
induced emesis
emesis
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2003302072A
Other languages
English (en)
Inventor
Enrico Braglia
Riccardo Braglia
Sergio Cantoreggi
Alberto Macciocchi
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Helsinn Healthcare SA
Original Assignee
Helsinn Healthcare SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=32326433&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AU2003302072(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Helsinn Healthcare SA filed Critical Helsinn Healthcare SA
Publication of AU2003302072A1 publication Critical patent/AU2003302072A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/473—Quinolines; Isoquinolines ortho- or peri-condensed with carbocyclic ring systems, e.g. acridines, phenanthridines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • G—PHYSICS
    • G06—COMPUTING OR CALCULATING; COUNTING
    • G06F—ELECTRIC DIGITAL DATA PROCESSING
    • G06F16/00—Information retrieval; Database structures therefor; File system structures therefor
    • G06F16/20—Information retrieval; Database structures therefor; File system structures therefor of structured data, e.g. relational data
    • G06F16/23—Updating
    • G06F16/2379—Updates performed during online database operations; commit processing

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Databases & Information Systems (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Theoretical Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Data Mining & Analysis (AREA)
  • Otolaryngology (AREA)
  • General Engineering & Computer Science (AREA)
  • General Physics & Mathematics (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU2003302072A 2002-11-15 2003-11-06 Palonosetron for the treatment of chemotherapy-induced emesis Abandoned AU2003302072A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US42682902P 2002-11-15 2002-11-15
US60/426,829 2002-11-15
PCT/IB2003/005567 WO2004045615A1 (en) 2002-11-15 2003-11-06 Palonosetron for the treatment of chemotherapy-induced emesis

Publications (1)

Publication Number Publication Date
AU2003302072A1 true AU2003302072A1 (en) 2004-06-15

Family

ID=32326433

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2003302072A Abandoned AU2003302072A1 (en) 2002-11-15 2003-11-06 Palonosetron for the treatment of chemotherapy-induced emesis

Country Status (6)

Country Link
US (2) US20060079545A1 (enExample)
JP (4) JP5690461B2 (enExample)
AU (1) AU2003302072A1 (enExample)
CA (1) CA2505990C (enExample)
DE (1) DE10393729T5 (enExample)
WO (1) WO2004045615A1 (enExample)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2340484T3 (es) * 2002-11-05 2010-06-04 Glaxo Group Limited Agentes antibacterianos.
US8598219B2 (en) 2003-01-30 2013-12-03 Helsinn Healthcare Sa Liquid pharmaceutical formulations of palonosetron
JO2735B1 (en) 2003-01-30 2013-09-15 هيلسين هيلث كير أس ايه. Liquid pharmaceutical formations of balloonosterone
MY143789A (en) * 2003-02-18 2011-07-15 Helsinn Healthcare Sa Use of palonosetron treating post- operative nausea and vomiting
KR101441459B1 (ko) * 2006-10-24 2014-09-18 헬신 헬쓰케어 에스.에이. 안정성 및 생체이용률이 개선된 염산 팔로노세트론을 포함하는 연질 캡슐
EP2099298A4 (en) * 2006-12-07 2010-01-06 Helsinn Healthcare Sa CRYSTALLINE AND AMORPHOUS FORMS OF PALONOSETRON HYDROCHLORIDE
JP2011518881A (ja) * 2008-04-28 2011-06-30 ゾゲニクス インコーポレーティッド 片頭痛の治療のための製剤
WO2009139411A1 (ja) 2008-05-15 2009-11-19 久光製薬株式会社 パロノセトロンを含有する経皮吸収製剤
US20100048607A1 (en) * 2008-08-25 2010-02-25 Chandrashekhar Kocherlakota Formulations comprising palonosetron
EP2364138A2 (en) * 2008-12-08 2011-09-14 Teva Pharmaceutical Industries Ltd. Palonosetron formulation
JP2013510843A (ja) 2009-11-13 2013-03-28 ヘルシン ヘルスケア ソシエテ アノニム パロノセトロン代謝産物先行出願との関連本出願は２００９年１１月１３日に出願された米国仮出願第６１／２６０，９１６号の優先権を主張する。
RS55206B1 (sr) 2009-11-18 2017-01-31 Helsinn Healthcare Sa Kompozicije za lečenje centralno posredovane mučnine i povraćanja
EP2722045B1 (en) 2009-11-18 2016-07-06 Helsinn Healthcare SA Compositions for treating centrally mediated nausea and vomiting
WO2016118540A1 (en) * 2015-01-20 2016-07-28 Xoc Pharmaceuticals, Inc. Treating and/or preventing emesis and/or nausea including acute and/or delayed nausea and/or emesis
JP6642377B2 (ja) * 2016-10-25 2020-02-05 ニプロ株式会社 液体製剤、及び、パロノセトロンの安定性を向上する方法

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US807381A (en) * 1905-01-10 1905-12-12 Auto Stopper Company Means for securing stoppers for vessels in their caps.
US1796729A (en) * 1930-04-18 1931-03-17 Aluminum Co Of America Closure
US2069075A (en) * 1934-04-20 1937-01-26 United Dairies London Ltd Bottle or like container
US2113176A (en) * 1936-03-26 1938-04-05 Guardian Safety Seal Company Sealed receptacle
US3314564A (en) * 1965-05-06 1967-04-18 West Co Container closure
US3601273A (en) * 1969-01-31 1971-08-24 Aluminum Co Of America Pilferproof closure with vertical weakening lines
DE2315962A1 (de) * 1972-04-05 1973-10-18 Metal Closures Ltd Verschlusskappenrohling fuer flaschen od. dgl.
US4695578A (en) * 1984-01-25 1987-09-22 Glaxo Group Limited 1,2,3,9-tetrahydro-3-imidazol-1-ylmethyl-4H-carbazol-4-ones, composition containing them, and method of using them to treat neuronal 5HT function disturbances
US4937247A (en) * 1985-04-27 1990-06-26 Beecham Group P.L.C. 1-acyl indazoles
EP0498466B1 (en) * 1985-04-27 2002-07-24 F. Hoffmann-La Roche Ag Indazole-3-carboxamide and -3-carboxylic acid derivatives
US5578628A (en) * 1985-06-25 1996-11-26 Glaxo Group Limited Medicaments for the treatment of nausea and vomiting
GB8516083D0 (en) * 1985-06-25 1985-07-31 Glaxo Group Ltd Heterocyclic compounds
US5240954A (en) * 1985-06-25 1993-08-31 Glaxo Group Limited Medicaments
US4906755A (en) * 1986-11-03 1990-03-06 Merrell Dow Pharmaceuticals Inc. Esters of hexahydro-8-hydroxy-2,6-methano-2H-quinolizin-3-(4H)-one and related compounds
US5011846A (en) * 1988-02-23 1991-04-30 Merrell Dow Pharmaceuticals Inc. Medicament compositions derived from quinolizine and quinolizinone and methods of use thereof
GB8914804D0 (en) * 1989-06-28 1989-08-16 Glaxo Group Ltd Process
US5344658A (en) * 1989-06-28 1994-09-06 Glaxo Group Limited Process and composition using ondansetron
HU218654B (hu) * 1989-11-28 2000-10-28 Syntex (U.S.A.) Inc. Triciklusos vegyületek, ezeket hatóanyagként tartalmazó gyógyászati készítmények és eljárás előállításukra
GB2277749B (en) * 1993-05-08 1996-12-04 Ciba Geigy Ag Fluorescent whitening of paper
GB9423588D0 (en) * 1994-11-22 1995-01-11 Glaxo Wellcome Inc Compositions
GB9423511D0 (en) * 1994-11-22 1995-01-11 Glaxo Wellcome Inc Compositions
US20030095926A1 (en) * 1997-10-01 2003-05-22 Dugger Harry A. Buccal, polar and non-polar spray or capsule containing drugs for treating disorders of the gastrointestinal tract or urinary tract
US6294548B1 (en) * 1998-05-04 2001-09-25 Hoffmann-La Roche Inc. Multidose vial formulations for administering endo-N-(9-methyl-9-azabicyclo[3.3.1]non-3-yl)-1-methyl-1H-indazole-3-carboxamide hydrochloride
US20030127420A1 (en) * 2002-01-09 2003-07-10 Klaus Schumacher Dual bottle closure
JO2735B1 (en) * 2003-01-30 2013-09-15 هيلسين هيلث كير أس ايه. Liquid pharmaceutical formations of balloonosterone
MY143789A (en) * 2003-02-18 2011-07-15 Helsinn Healthcare Sa Use of palonosetron treating post- operative nausea and vomiting

Also Published As

Publication number Publication date
US20060079545A1 (en) 2006-04-13
CA2505990A1 (en) 2004-06-03
JP2016199588A (ja) 2016-12-01
JP2012131811A (ja) 2012-07-12
US20110178118A1 (en) 2011-07-21
JP5690461B2 (ja) 2015-03-25
CA2505990C (en) 2009-05-19
WO2004045615A1 (en) 2004-06-03
JP6342960B2 (ja) 2018-06-13
JP2015143266A (ja) 2015-08-06
JP2006508977A (ja) 2006-03-16
JP5893950B2 (ja) 2016-03-23
DE10393729T5 (de) 2005-10-13

Similar Documents

Publication Publication Date Title
AU2002348135A1 (en) Methods for the treatment of addiction
AU2003226168A1 (en) Fluorochemical treatment for silicon articles
AU2003274342A1 (en) Compositions for the treatment of autoimmune disorders
AU2003217275A1 (en) Azabicyclic compounds for the treatment of disease
AU2003302072A1 (en) Palonosetron for the treatment of chemotherapy-induced emesis
AU2003302035A1 (en) Formulations used for the treatment of substrate surfaces
AU2003258145A1 (en) Substituted phenylindoles for the treatment of hiv
AU2002240359A1 (en) Pharmaceutical composition for the treatment of alopecia
AU2003241599A1 (en) Compositions and methods for the treatment of hemophilia a
AU2003224002A1 (en) Drugs for the arthritis treatment
IL165773A0 (en) Use of nefopam for the treatment of nausea or emesis
EP1670894B8 (en) Compositions including different types of transfer factor, methods for making the compositions, and methods of treatment using the compositions
AU2003260778A1 (en) Treatment of pipes
AU2003903242A0 (en) Process for the treatment of wood
AU2003233820A1 (en) Method for the treatment of starch
AU2003223538A1 (en) Methods for the treatment of cancer
AU2003260983A1 (en) Processes for the preparation of s-(-)-amlodipine
AU2003220026A1 (en) Methods and compositions for the treatment of ischemia
AU2003258983A1 (en) Combinations for the treatment of fungal infections
AU2003205452A1 (en) Bmp inhibitors for the treatment of spondyloarthropathies
AU2003270202A1 (en) Pharmaceutical compositions increasing camp useful for the treatment of cancers
EG24959A (en) Indoles useful in the treatment of androgenreceptor related diseases.
AU2003266960A1 (en) Composition for the treatment of pain, especially for the treatment of articular pain
AU2003240174A1 (en) Compositions for the treatment of edematous-firbrosclerotic panniculopathy
AU2003260723A1 (en) Use of vinca alkaloyds, taxane, cryptophycine, ephitoline or eleutherobine for treating alzheimer

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase